Our unique analytics are driving the next wave of precision medicine insights – finding new treatment opportunities for patients’ unmet medical needs in metabolic, inflammatory, respiratory, cardiovascular, women’s health, neurodegenerative and neuropsychiatric diseases
About usBetter understanding of complex disease biology
We believe that deciphering the complex combinatorial influences on disease biology in patient sub-groups is at the heart of successful drug programs
High-resolution stratification of populations and people
Accurately defining sub-groups of patients enables us to understand their disease risks and drivers, select the right patients for trials, and the right treatment for a patient
New disease insights through collaboration
We bring together data partners, charities, healthcare and life science companies, and Key Opinion Leaders to advance chronic disease outcomes
Why PrecisionLife?
Our unique combinatorial analytics platform unpicks the complex causes of disease and delivers a high-resolution patient stratification based on deep insights into novel target biology.
We bring together data, technology, industry experts and collaborative partners to transform our understanding of chronic disease and find new therapy options for patients.
PrecisionLife’s platform provides detailed contextual information on the SNPs, genes and pathways driving disease in patient sub-groups, and their active chemistry, tissue expression, mechanism of action, IP, clinical trials and more.
Pharma & Biotech
Selecting the right disease biology and drug target is crucial to innovative drug discovery
Clinical Development
Recruiting the right patients is critical to demonstrating efficacy and running smaller, faster and more successful clinical trials
Healthcare
Understanding the personal factors influencing chronic disease risk, progression rate and treatment response is vital to improved care
Latest Disease Studies
Read all Disease StudiesLatest News & Media
View all
News
Publications
Events
UK BioIndustry Association launches first TechBio company report
OXFORD, UK: PrecisionLife featured as a case study of how a data-driven techbio company is transforming drug discovery and…
15/10/21
Best Chronic Disease Biology Company 2021 awarded to PrecisionLife
OXFORD, UK The International Life Sciences Awards has named PrecisionLife as the Best Chronic Disease Biology R&D Company 2021.
20/09/21
Ray Pawlicki, Previously CIO at Biogen and Novartis, Joins PrecisionLife as Executive Chair to Accelerate Strategic Expansion
OXFORD, UK June 24th, 2021 –
24/06/21
BIA Bioscience Forum
London, 14 October 2021 PrecisionLife CEO, Dr Steve Gardner, will join an expert panel at the BIA Bioscience Forum…
6/10/21
WEBINAR: Disease Mechanisms and Target Discovery
PrecisionLife CEO, Dr Steve Gardner, joins Cyclica CEO, Naheed Kurji in a webinar exploring Disease Mechanisms and Target Discovery….
6/10/21
Neuropsychiatric Drug Development Summit
Online, 29-30 September 2021 Members of the PrecisionLife team will join leaders from the likes of Sunovion, Merck, Takeda,…
24/09/21
Why does chronic disease drug discovery & development need fixing?
The blockbuster model for drug discovery and development in chronic diseases is inefficient and costly. We need a new…
12/10/21
Anyone for tea? Why Alzheimer’s drug discovery might be targeting the impossible
Unique approach to precision medicine could reverse the trend in Alzheimer’s disease drug discovery and development Clinical trials in…
27/09/21
Complexity of disease biology gives opportunities for drug discovery
Late-stage clinical trials incur the biggest costs of bringing new drugs to market. Increasingly clinical trial failures happen late….
1/09/21